

Tsutomu Takeuchi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7713293/tsutomu-takeuchi-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

572 papers	19,338 citations	63 h-index	119 g-index
657 ext. papers	23,429 ext. citations	3.8 avg, IF	6.72 L-index

#	Paper	IF	Citations
572	'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 70	5.7	1
571	Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: a retrospective, single-centre cohort study.. <i>Modern Rheumatology</i> , 2021 ,	3.3	1
570	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
569	Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.. <i>Modern Rheumatology</i> , 2021 ,	3.3	1
568	Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 1419-1426	2.3	
567	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	8
566	Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. <i>Rheumatology</i> , 2021 , 60, e73-e75	3.9	1
565	Safety and tolerability of ultrasound-guided synovial needle biopsy in Japanese arthritis patients. <i>Modern Rheumatology</i> , 2021 , 31, 960-965	3.3	0
564	High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021 , 40, 3615-3626	3.9	2
563	Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study. <i>Modern Rheumatology</i> , 2021 , 1-14	3.3	3
562	Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. <i>Rheumatology and Therapy</i> , 2021 , 8, 425-442	4.4	3
561	Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. <i>Rheumatology</i> , 2021 , 60, 5247-5256	3.9	6
560	Peripheral TIGIT+ T Follicular Helper Cells That Produce High Levels of Interleukin-21 OX40 Represent Disease Activity in IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2021 , 12, 651357	8.4	8
559	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. <i>Journal of Rheumatology</i> , 2021 , 48, 1663-1671	4.1	2
558	Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review. <i>Modern Rheumatology</i> , 2021 , 1-7	3.3	0
557	Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1491-1493	2.4	1
556	Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review. <i>Autoimmunity Reviews</i> , 2021 , 20, 102805	13.6	2

555	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. <i>Drug Safety</i> , 2021 , 44, 711-722	5.1	3
554	Proton Pump Inhibitor and Tacrolimus Uses are Associated With Hypomagnesemia in Connective Tissue Disease: a Potential Link With Renal Dysfunction and Recurrent Infection. <i>Frontiers in Pharmacology</i> , 2021 , 12, 616719	5.6	1
553	Identification of neutrophil α -integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses. <i>Arthritis Research and Therapy</i> , 2021 , 23, 136	5.7	0
552	Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-7	5.4	1
551	Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
550	Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka ' by Berkhout. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e173	2.4	
549	Long-term Safety and Effectiveness of Tacrolimus in Patients With Lupus Nephritis: 5-year Interim Postmarketing Surveillance Study in Japan (TRUST). <i>Journal of Rheumatology</i> , 2021 , 48, 74-81	4.1	5
548	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. <i>Modern Rheumatology</i> , 2021 , 31, 53-60	3.3	0
547	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
546	Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients With Rheumatoid Arthritis-Associated and Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021 , 73, 576-586	9.5	2
545	Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 587-595	9.5	3
544	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. <i>Modern Rheumatology</i> , 2021 , 31, 543-555	3.3	3
543	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021 , 31, 534-542	3.3	1
542	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2021 , 1-16	3.3	2
541	Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 651-659	2.4	1
540	Lymphadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker. <i>Rheumatology</i> , 2021 , 60, 967-975	3.9	8
539	Distinct features between HLA-DR+ and HLA-DR- PD-1hi CXCR5- T peripheral helper cells in seropositive rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 451-460	3.9	1
538	Radiographic and clinical effects of 10 mg and 25 mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021 , 31, 319-325	3.3	0

537	Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis? <i>Journal of Human Genetics</i> , 2021 , 66, 219-223	4.3	4
536	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. <i>Modern Rheumatology</i> , 2021 , 31, 34-41	3.3	4
535	Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. <i>Scientific Reports</i> , 2021 , 11, 222	4.9	9
534	Refractory IgG4-related Pleural Disease with Chylothorax: A Case Report and Literature Review. <i>Internal Medicine</i> , 2021 , 60, 2135-2143	1.1	1
533	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021 , 7,	5.9	1
532	Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1307	6.8	2
531	Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). <i>Arthritis Research and Therapy</i> , 2021 , 23, 9	5.7	4
530	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2021 , 31, 783-789	3.3	4
529	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. <i>Rheumatology</i> , 2021 , 60, 5185-5193	3.9	1
528	Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 221	5.7	1
527	IgG4-related disease and idiopathic multicentric Castleman's disease: confusable immune-mediated disorders. <i>Rheumatology</i> , 2021 ,	3.9	1
526	Molecular remission at T cell level in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2021 , 11, 16694	4.9	0
525	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. <i>Arthritis Research and Therapy</i> , 2021 , 23, 220	5.7	
524	Salivary gland involvement in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2021 , 20, 102940	13.6	3
523	Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021 , 20, 102884	13.6	11
522	An update on the pathogenic role of IL-6 in rheumatic diseases. <i>Cytokine</i> , 2021 , 146, 155645	4	2
521	Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4 Treg axis during remission of crescentic glomerulonephritis. <i>Clinical and Translational Immunology</i> , 2020 , 9, e1203	6.8	3
520	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2020 , 22, 252	5.7	5

519	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology, The</i> , 2020 , 2, e347-e357	14.2	25
518	Interleukin-4 as an emerging therapeutic target for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
517	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	24
516	Longitudinal immune cell monitoring identified CD14 CD16 intermediate monocyte as a marker of relapse in patients with ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 145	5.7	7
515	Effectiveness of tocilizumab in Behcet's disease: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 797-804	5.3	20
514	Eldecacitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). <i>Journal of Bone and Mineral Metabolism</i> , 2020 , 38, 522-532	2.9	8
513	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. <i>Arthritis Research and Therapy</i> , 2020 , 22, 47	5.7	14
512	Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 46	5.7	10
511	Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	6
510	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1607-1620	9.5	56
509	Identification of novel genes associated with dysregulation of B cells in patients with primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020 , 22, 153	5.7	14
508	Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2020 , 22, 157	5.7	6
507	Aryl hydrocarbon receptor signals attenuate lung fibrosis in the bleomycin-induced mouse model for pulmonary fibrosis through increase of regulatory T cells. <i>Arthritis Research and Therapy</i> , 2020 , 22, 20	5.7	8
506	Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 521-525	5.3	10
505	Etiology of IgG4-Related Pulmonary Hypertension. <i>Cardiology</i> , 2020 , 145, 263-266	1.6	1
504	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 316-324	2.3	1
503	CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 671-674	2.4	5
502	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. <i>Rheumatology</i> , 2020 , 59, 3303-3313	3.9	25

501	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	3.4	851
500	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 335-345	8.1	164
499	Response to: 'Some concerns from Turkey' by Bilgin. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e16	2.4	3
498	Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 150-158	2.4	13
497	Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. <i>Rheumatology</i> , 2020 , 59, 545-553	3.9	7
496	Pursuit and New Trend in Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 80a-86a	0	
495	Pursuit and New Trend in Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 1669-1684	0	
494	10) From the Perspective of Rheumatology. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 2040-2045	0	
493	4. Rheumatic and Collagen-vascular Diseases: Updates on Diagnosis and Treatment. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 486-495	0	
492	Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. <i>International Immunology</i> , 2020 , 32, 163-174	4.9	8
491	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 94-102	2.4	7
490	Characteristics and prognosis of ANCA-positive retroperitoneal fibrosis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2020 , 19, 102642	13.6	7
489	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020 , 6,	5.9	10
488	Value of labial salivary gland histopathology for diagnosis of Sjögren's syndrome in patients with anti-centromere antibody positivity. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1024-1029	2.3	1
487	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. <i>RMD Open</i> , 2020 , 6,	5.9	4
486	Development of an intravital imaging system for the synovial tissue reveals the dynamics of CTLA-4 Ig in vivo. <i>Scientific Reports</i> , 2020 , 10, 13480	4.9	5
485	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1290-1297	2.4	29
484	Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. <i>Annals of Hematology</i> , 2020 , 99, 2463-2475	3	3

483	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1255-1257	2.3	9
482	Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	5
481	Lupus aortitis: A fatal, inflammatory cardiovascular complication in systemic lupus erythematosus. <i>Lupus</i> , 2020 , 29, 1652-1654	2.6	3
480	Does microbiome contribute to HLA-B52-positive Takayasu arteritis?. <i>Modern Rheumatology</i> , 2020 , 30, 213-217	3.3	5
479	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020 , 30, 36-43	3.3	31
478	Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. <i>Arthritis Care and Research</i> , 2020 , 72, 1112-1121	4.7	14
477	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. <i>Modern Rheumatology</i> , 2020 , 30, 525-531	3.3	4
476	Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A analysis of the SURPRISE study. <i>Modern Rheumatology</i> , 2020 , 30, 442-449	3.3	2
475	Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020 , 30, 259-268	3.3	2
474	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and 12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. <i>Modern Rheumatology</i> , 2020 , 30, 424-433	3.3	
473	Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab. <i>Rheumatology</i> , 2020 , 59, 440-442	3.9	5
472	Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. <i>Rheumatology</i> , 2019 , 58, 1034-1039	3.9	13
471	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1305-1319	2.4	61
470	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17
469	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 878-891	9.5	38
468	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1042-1055	9.5	82
467	Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: A potential role of M2 polarization.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 137-148	2.3	
466	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	25

465	Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1346-1356	2.4	25
464	Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or	5.7	34
463	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 899-907	2.4	54
462	Pulmonary Vein Vasculitis Presenting as Multiple Pulmonary Nodules in a Patient with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 323-324	4.1	1
461	Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab. <i>Inflammation and Regeneration</i> , 2019 , 39, 5	10.9	0
460	Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2508-2515	1.9	4
459	Effectiveness and safety of initiating adalimumab plus 12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. <i>Modern Rheumatology</i> , 2019 , 29, 572-580	3.3	6
458	Ground Glass Opacity with Mixed Consolidation on Chest Computed Tomography Reflects the Severe Condition of Pneumocystis Pneumonia in Association with a Poor Prognosis in Patients with Connective Tissue Diseases. <i>Internal Medicine</i> , 2019 , 58, 3379-3383	1.1	1
457	Characteristics and prognosis of IgG4-related periaortitis/periarteritis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2019 , 18, 102354	13.6	30
456	Subtypes in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor. <i>Clinical Rheumatology</i> , 2019 , 38, 3493-3499	3.9	0
455	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 315-325	27.4	117
454	Body mass index associates with disease relapse in patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 1782-1786	2.3	3
453	THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS 2019 ,		5
452	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1320-1332	2.4	65
451	Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. <i>Nature Immunology</i> , 2019 , 20, 1631-1643	19.1	51
450	Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 304	5.7	18
449	Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019 , 59, 145-155	1.9	9
448	IgG4-Related Disease: A Growing Appreciation of Follicular Helper T Cell Expansion. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00076	4.2	2

447	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019 , 46, 7-18	4.1	150
446	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. <i>Modern Rheumatology</i> , 2019 , 29, 747-753	3.3	7
445	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 171-178	2.4	36
444	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. <i>Rheumatology</i> , 2019 , 58, 997-1005	3.9	12
443	Ten-year observation of patients with primary Sjögren's syndrome: Initial presenting characteristics and the associated outcomes. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 929-933	2.3	10
442	Development of the Asia Pacific Lupus Collaboration cohort. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 425-433	2.3	14
441	Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e134	2.4	
440	Initial presentation determines clinical entity in patients with anti-centromere antibody positivity. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 103-107	2.3	2
439	Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 14	5.7	9
438	Impact of subclinical synovitis in ankles and feet detected by ultrasonography in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 62-67	2.3	4
437	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. <i>Modern Rheumatology</i> , 2019 , 29, 756-766	3.3	7
436	Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. <i>Clinical and Experimental Nephrology</i> , 2019 , 23, 387-394	2.5	4
435	Effectiveness of tacrolimus on IgG4-related disease. <i>Modern Rheumatology</i> , 2019 , 29, 892-894	3.3	6
434	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). <i>Modern Rheumatology</i> , 2019 , 29, 306-313	3.3	1
433	Secukinumab after anti-tumour necrosis factor- α therapy: a phase III study in active rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 276-281	1.9	26
432	Persistent fever and destructive arthritis caused by dialysis-related amyloidosis: A case report. <i>Medicine (United States)</i> , 2018 , 97, e9359	1.8	1
431	Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment. <i>Clinical Rheumatology</i> , 2018 , 37, 1107-1110	3.9	19
430	Splicing variant of augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 602-611	2.4	31

429	Clinical practice guideline for Sjögren's syndrome 2017. <i>Modern Rheumatology</i> , 2018 , 28, 383-408	3.3	27
428	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. <i>Modern Rheumatology</i> , 2018 , 28, 941-949	3.3	2
427	Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials. <i>Modern Rheumatology</i> , 2018 , 28, 960-967	3.3	10
426	Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study. <i>Modern Rheumatology</i> , 2018 , 28, 611-620	3.3	7
425	Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. <i>Circulation Journal</i> , 2018 , 82, 546-554	2.9	23
424	Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. <i>Arthritis Research and Therapy</i> , 2018 , 20, 42	5.7	11
423	Tendonitis on the Fingers in Behçet's Disease. <i>Internal Medicine</i> , 2018 , 57, 2599	1.1	
422	IgG4-Related Disease: Beyond Glucocorticoids. <i>Drugs and Aging</i> , 2018 , 35, 275-287	4.7	32
421	Follicular helper T cells in the pathogenesis of IgG4-related disease. <i>Rheumatology</i> , 2018 , 57, 236-245	3.9	46
420	Safety, pharmacokinetics, and efficacy of E6011, an anti fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018 , 28, 58-65	3.3	42
419	Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan. <i>Modern Rheumatology</i> , 2018 , 28, 48-57	3.3	9
418	Biomarkers as a treatment guide in rheumatoid arthritis. <i>Clinical Immunology</i> , 2018 , 186, 59-62	9	16
417	Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results. <i>Modern Rheumatology</i> , 2018 , 28, 85-94	3.3	4
416	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. <i>Modern Rheumatology</i> , 2018 , 28, 39-47	3.3	3
415	Increased proportion of a CD38IgD B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjögren's syndrome. <i>Clinical Immunology</i> , 2018 , 187, 85-91	9	6
414	CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1386-1387	2.4	23
413	Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2018 , 37, 765-771	3.9	9
412	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 165-174	2.4	120

411	Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1143-1152	1.9	37
410	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018 , 28, 9-16	3.3	52
409	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <i>Frontiers in Immunology</i> , 2018 , 9, 621	8.4	16
408	Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. <i>Nature Communications</i> , 2018 , 9, 2755	17.4	63
407	Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease. <i>Cytokine</i> , 2018 , 110, 416-419	4	21
406	IgG4-related fibrosing mediastinitis diagnosed with computed tomography-guided percutaneous needle biopsy: Two case reports and a review of the literature. <i>Medicine (United States)</i> , 2018 , 97, e10935 ^{1.8}		31
405	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. <i>Modern Rheumatology</i> , 2018 , 28, 770-779	3.3	2
404	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , 2018 , 28, 642-648	3.3	11
403	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018 , 28, 583-591	3.3	26
402	Difosumab associ�aux bDMARD : efficacit�sur la progression radiographique dans la polyarthrite rhumato�de. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018 , 85, 300-302	0.1	
401	Targeting IL-6: A review of data 2018 , 2, 12-18		3
400	Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. <i>RMD Open</i> , 2018 , 4, e000731	5.9	6
399	Considering new lessons about the use of IL-6 inhibitors in arthritis 2018 , 2, 7-11		2
398	Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , 2018 , 4, e000813	5.9	6
397	Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies. <i>Inflammation and Regeneration</i> , 2018 , 38, 20	10.9	2
396	Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sj�gren's Syndrome. <i>Rheumatology and Therapy</i> , 2018 , 5, 499-505	4.4	15
395	Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1720-1729	2.4	83
394	IL-6, IL-17 and Stat3 are required for auto-inflammatory syndrome development in mouse. <i>Scientific Reports</i> , 2018 , 8, 15783	4.9	12

393	Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study. <i>Biological and Pharmaceutical Bulletin</i> , 2018 , 41, 1414-1422	2.3	4
392	Adolescent PR3-ANCA-positive hypertrophic pachymeningitis: A case report and review of the literature. <i>Medicine (United States)</i> , 2018 , 97, e0521	1.8	10
391	Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1626-1633	9.5	18
390	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1066-1071	2.4	32
389	Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 157-164	2.2	8
388	Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017 , 84, 379-380	2.9	24
387	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUEAU Study. <i>Advances in Therapy</i> , 2017 , 34, 686-702	4.1	15
386	CD14CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 28	5.7	48
385	Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. <i>RMD Open</i> , 2017 , 3, e000363	5.9	49
384	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	7.4	1649
383	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1348-1356	2.4	25
382	Survey on attitudes regarding EULAR recommendations for the role of nurses involved in medical care of patients with chronic inflammatory arthritis in Japan. <i>Modern Rheumatology</i> , 2017 , 27, 886-893	3.3	4
381	Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. <i>BioDrugs</i> , 2017 , 31, 299-316	7.9	161
380	Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. <i>Rheumatology</i> , 2017 , 56, 940-946	3.9	29
379	Importance of Obtaining Remission for Work Productivity and Activity of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017 , 44, 1112-1117	4.1	11
378	Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1458-1466	2.4	47
377	Pulmonary Cryptococcosis Developed from a Nodule after Treatment with Infliximab for Arthritis Associated with Ulcerative Colitis. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 603-605	4.7	2
376	Pre-treatment interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients. <i>Rheumatology</i> , 2017 , 56, 1089-1094	3.9	13

375	Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1980-1985	2.4	26
374	Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017 , 44, 553-557	4.1	6
373	Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 56	5.7	11
372	Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis. <i>International Immunology</i> , 2017 , 29, 511-517	4.9	14
371	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017 , 3, e000465	5.9	7
370	Comparison of the Clinical Characteristics of Pneumocystis Pneumonia between Patients with Rheumatoid Arthritis Being Treated with Biologics and Those Being Treated without Biologics. <i>BioMed Research International</i> , 2017 , 2017, 3710652	3	7
369	High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 194	5.7	32
368	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. <i>Arthritis Research and Therapy</i> , 2017 , 19, 208	5.7	30
367	Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 218	5.7	29
366	A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 231	5.7	6
365	Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017 , 93, 600-608	4	7
364	Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2001-2008	2.4	45
363	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. <i>Contemporary Clinical Trials Communications</i> , 2017 , 8, 49-54	1.8	4
362	Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab. <i>Annals of Hematology</i> , 2017 , 96, 2117-2119	3	11
361	Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease. <i>RMD Open</i> , 2017 , 3, e000432	5.9	25
360	Secukinumab in Active Rheumatoid Arthritis after Anti-TNF Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. <i>Rheumatology and Therapy</i> , 2017 , 4, 475-488	4.4	21
359	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. <i>Scientific Reports</i> , 2017 , 7, 15035	4.9	17
358	Proteinuria selectivity index as a prognostic biomarker in lupus nephritis. <i>Lupus</i> , 2017 , 26, 656-660	2.6	4

357	Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2017 , 27, 778-781	3.3	2
356	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. <i>Modern Rheumatology</i> , 2017 , 27, 284-291	3.3	6
355	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. <i>Modern Rheumatology</i> , 2017 , 27, 237-245	3.3	46
354	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017 , 69, 506-517	9.5	216
353	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. <i>Modern Rheumatology</i> , 2017 , 27, 217-226	3.3	23
352	Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. <i>Modern Rheumatology</i> , 2017 , 27, 787-794	3.3	5
351	Polymyositis with elevated serum IgG4 levels and abundant IgG4+ plasma cell infiltration: A case report and literature review. <i>Medicine (United States)</i> , 2017 , 96, e8710	1.8	10
350	Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. <i>Die Pharmazie</i> , 2017 , 72, 22-28	1.5	4
349	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. <i>Modern Rheumatology</i> , 2016 , 26, 80-6	3.3	28
348	Polychondritis presenting with oculomotor and abducens nerve palsies as the initial manifestation. <i>Modern Rheumatology</i> , 2016 , 26, 790-3	3.3	5
347	Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. <i>Arthritis Research and Therapy</i> , 2016 , 18, 167	5.7	104
346	Tofeformant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies. <i>Journal of Rheumatology</i> , 2016 , 43, 1637-42	4.1	14
345	IgG4-related disease involving vital organs diagnosed with lip biopsy: A case report and literature review. <i>Medicine (United States)</i> , 2016 , 95, e3970	1.8	14
344	Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 34	5.7	90
343	Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. <i>Rheumatology and Therapy</i> , 2016 , 3, 155-166	4.4	5
342	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). <i>Rheumatology and Therapy</i> , 2016 , 3, 129-141	4.4	3
341	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
340	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016 , 26, 491-8	3.3	53

339	Anti-signal recognition particle antibody in patients without inflammatory myopathy: a survey of 6180 patients with connective tissue diseases. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 36-40	1.9	5
338	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1057-64	2.4	101
337	Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2016 , 26, 676-80	3.3	2
336	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. <i>Modern Rheumatology</i> , 2016 , 26, 15-23	3.3	36
335	Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016 , 35, 2829-2834	3.9	15
334	Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016 , 26, 473-80	3.3	7
333	A unique case of polymyositis with anti-signal recognition particle antibody complicated by subacute interstitial lung disease and subluxing arthropathy, resembling anti-synthetase syndrome. <i>Modern Rheumatology</i> , 2016 , 26, 979-980	3.3	6
332	Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. <i>Cytokine</i> , 2016 , 78, 87-93	4	29
331	Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis. <i>Clinical Rheumatology</i> , 2016 , 35, 495-500	3.9	5
330	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. <i>Modern Rheumatology</i> , 2016 , 26, 651-61	3.3	19
329	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 75-83	2.4	66
328	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH study. <i>Modern Rheumatology</i> , 2016 , 26, 481-88	3.3	11
327	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. <i>Modern Rheumatology</i> , 2016 , 26, 323-30	3.3	6
326	Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 112	5.7	11
325	Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2016 , 18, 159	5.7	30
324	Resolution of elevated circulating regulatory T cells by corticosteroids in patients with IgG4-related dacryoadenitis and sialoadenitis. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 430-2	2.3	8
323	Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis. <i>Internal Medicine</i> , 2016 , 55, 1661-5	1.1	15
322	Intriguing Findings of the Muscle on Magnetic Resonance Imaging in Polyarteritis Nodosa. <i>Internal Medicine</i> , 2016 , 55, 3197-3200	1.1	2

321	Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e71	2.4	2
320	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1917-1923	2.4	69
319	Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2016 , 18, 106	5.7	30
318	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study. <i>RMD Open</i> , 2016 , 2, e000189	5.9	17
317	Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. <i>Rheumatology International</i> , 2016 , 36, 881-9	3.6	39
316	Enlargement of thymoma triggers overlapping autoimmune diseases. <i>Autoimmunity Reviews</i> , 2016 , 15, 1200-1201	13.6	3
315	Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016 , 43, 1984-1988	4.1	15
314	Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2016 , 43, 1825-1831	4.1	46
313	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 983-90	2.4	111
312	Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation. <i>International Immunopharmacology</i> , 2016 , 39, 273-279	5.8	5
311	Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. <i>Modern Rheumatology</i> , 2015 , 25, 31-7	3.3	16
310	Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. <i>Modern Rheumatology</i> , 2015 , 25, 43-9	3.3	8
309	Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. <i>Arthritis Research and Therapy</i> , 2015 , 17, 10	5.7	71
308	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon. <i>Rheumatology</i> , 2015 , 54, 349-58	3.9	11
307	An unusual association between focal segmental sclerosis and lupus nephritis: a distinct concept from lupus podocytopathy?. <i>CEN Case Reports</i> , 2015 , 4, 70-75	1	2
306	Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. <i>Modern Rheumatology</i> , 2015 , 25, 665-71	3.3	9
305	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015 , 25, 817-24	3.3	62
304	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. <i>Modern Rheumatology</i> , 2015 , 25, 514-21	3.3	93

303	Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. <i>Modern Rheumatology</i> , 2015 , 25, 173-86	3.3	12
302	Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. <i>Cytokine</i> , 2015 , 75, 222-7	4	11
301	Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. <i>Arthritis Research and Therapy</i> , 2015 , 17, 104	5.7	18
300	The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study. <i>Modern Rheumatology</i> , 2015 , 25, 401-4	3.3	30
299	Leucine-rich α 2-glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2056-60	9.5	44
298	Polarization diversity of human CD4+ stem cell memory T cells. <i>Clinical Immunology</i> , 2015 , 159, 107-17	9	26
297	Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan. <i>Modern Rheumatology</i> , 2015 , 25, 495-502	3.3	3
296	Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 498-507	9.5	45
295	Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. <i>Modern Rheumatology</i> , 2015 , 25, 21-30	3.3	31
294	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. <i>Rheumatology</i> , 2015 , 54, 683-91	3.9	35
293	Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015 , 67, 1354-62	4.7	20
292	Crohn's Disease in which the Patient Developed Aortitis during Treatment with Adalimumab. <i>Internal Medicine</i> , 2015 , 54, 1725-32	1.1	4
291	4. Progress in Rheumatoid Arthritis Therapy and Future Perspective. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015 , 104, 84a-88a	0	
290	Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review. <i>Internal Medicine</i> , 2015 , 54, 1131-4	1.1	11
289	4. Progress in Rheumatoid Arthritis Therapy and Future Perspective. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015 , 104, 1773-1782	0	2
288	Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 126	3.5	2
287	The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2591-600	9.5	63
286	Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. <i>RMD Open</i> , 2015 , 1, e000162	5.9	13

285	Number of Circulating Follicular Helper 2 T Cells Correlates With IgG4 and Interleukin-4 Levels and Plasmablast Numbers in IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2476-81	9.5	128
284	Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 768-75	2.3	1
283	Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study. <i>Journal of Rheumatology</i> , 2015 , 42, 599-607	4.1	7
282	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. <i>Modern Rheumatology</i> , 2015 , 25, 11-20	3.3	11
281	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015 , 17, 74	5.7	42
280	Early achievement of complete renal response predicts good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III or IV. <i>Modern Rheumatology</i> , 2015 , 25, 714-8	3.3	10
279	Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). <i>PLoS ONE</i> , 2015 , 10, e0145468	3.7	12
278	Subclinical labial salivary gland involvement in IgG4-related disease affected with vital organs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 949-50	2.2	12
277	Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. <i>Journal of Rheumatology</i> , 2014 , 41, 1061-6	4.1	27
276	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 536-43	2.4	74
275	Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs. <i>Modern Rheumatology</i> , 2014 , 24, 744-53	3.3	9
274	Response to: 'When is it not ethical to withhold treatment for rheumatoid arthritis?' by Dr Yusuf Yazici. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e26	2.4	
273	Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 945-7	2.4	29
272	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Oencia() as Biological Intensive Treatment for RA (ORBIT) study. <i>Modern Rheumatology</i> , 2014 , 24, 754-62	3.3	12
271	A paradigm shift in rheumatoid arthritis over the past decade. <i>Internal Medicine</i> , 2014 , 53, 1895-903	1.1	17
270	The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. <i>PLoS ONE</i> , 2014 , 9, e85062	3.7	82
269	Mice lacking inositol 1,4,5-trisphosphate receptors exhibit dry eye. <i>PLoS ONE</i> , 2014 , 9, e99205	3.7	28
268	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2014 , 24, 8-16	3.3	21

267	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014 , 24, 552-60	3.3	31
266	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. <i>Modern Rheumatology</i> , 2014 , 24, 399-404	3.3	12
265	Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. <i>Journal of Rheumatology</i> , 2014 , 41, 15-23	4.1	131
264	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. <i>Modern Rheumatology</i> , 2014 , 24, 390-8	3.3	63
263	Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. <i>Modern Rheumatology</i> , 2014 , 24, 885-91	3.3	13
262	Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. <i>Modern Rheumatology</i> , 2014 , 24, 561-6	3.3	8
261	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. <i>Modern Rheumatology</i> , 2014 , 24, 734-43	3.3	8
260	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. <i>Modern Rheumatology</i> , 2014 , 24, 725-33	3.3	8
259	Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan. <i>Modern Rheumatology</i> , 2014 , 24, 464-70	3.3	37
258	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. <i>Rheumatology</i> , 2014 , 53, 904-13	3.9	24
257	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. <i>Modern Rheumatology</i> , 2014 , 24, 715-24	3.3	37
256	Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. <i>Rheumatology</i> , 2014 , 53, 1120-4	3.9	8
255	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. <i>Modern Rheumatology</i> , 2014 , 24, 17-25	3.3	86
254	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. <i>Modern Rheumatology</i> , 2014 , 24, 26-32	3.3	16
253	Overview of lupus nephritis management guidelines and perspective from Asia. <i>Nephrology</i> , 2014 , 19, 11-20	2.2	48
252	Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. <i>BMC Gastroenterology</i> , 2013 , 13, 54	3	13
251	Reduction of plasma IL-6 but not TNF- α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. <i>Clinical Rheumatology</i> , 2013 , 32, 1661-6	3.9	52
250	CD247 variants and single-nucleotide polymorphisms observed in systemic lupus erythematosus patients. <i>Rheumatology</i> , 2013 , 52, 1551-5	3.9	11

249	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013 , 16, 625-36	2.3	25
248	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. <i>Modern Rheumatology</i> , 2013 , 1	3.3	1
247	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013 , 1	3.3	1
246	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. <i>Modern Rheumatology</i> , 2013 , 1	3.3	5
245	Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. <i>Modern Rheumatology</i> , 2013 , 23, 97-103	3.3	8
244	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013 , 23, 623-633	3.3	28
243	Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. <i>Modern Rheumatology</i> , 2013 , 23, 634-645	3.3	7
242	Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. <i>Modern Rheumatology</i> , 2013 , 23, 226-235	3.3	23
241	Osteolytic change of distal interphalangeal joints and sacroiliac joints in subluxing arthropathy associated with anti-Jo-1 antibody. <i>Joint Bone Spine</i> , 2013 , 80, 544-5	2.9	1
240	Atteinte ostéolytique des articulations interphalangiennes distales et sacro-iliaques dans une arthropathie subluxante associée à des anticorps anti-Jo-1. <i>Revue Du Rhumatisme (Edition Française)</i> , 2013 , 80, 528-529	0.1	
239	Interferon γ -targeted therapy. <i>Japanese Journal of Clinical Immunology</i> , 2013 , 36, 181-8		
238	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013 , 23, 1045-1052	3.3	7
237	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , 2013 , 23, 945-952	3.3	19
236	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1468-67	2.4	43
235	Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , 2013 , 40, 1658-68	4.1	10
234	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. <i>Modern Rheumatology</i> , 2013 , 23, 219-225	3.3	21
233	A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 310-2	2.4	6
232	American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints. <i>Journal of Rheumatology</i> , 2013 , 40, 1254-8	4.1	5

231	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. <i>Modern Rheumatology</i> , 2013 , 23, 1211-1220	3.3	16
230	Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. <i>Modern Rheumatology</i> , 2013 , 23, 97-103	3.3	5
229	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , 2013 , 23, 945-52	3.3	3
228	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. <i>Modern Rheumatology</i> , 2013 , 23, 1045-52	3.3	1
227	Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. <i>Modern Rheumatology</i> , 2013 , 23, 226-35	3.3	15
226	Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. <i>Modern Rheumatology</i> , 2013 , 23, 634-45	3.3	6
225	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2013 , 23, 623-33	3.3	18
224	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. <i>Modern Rheumatology</i> , 2013 , 23, 219-25	3.3	10
223	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. <i>Modern Rheumatology</i> , 2013 , 23, 1211-20	3.3	7
222	Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 115-25	6.1	17
221	CD3 defects in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71 Suppl 2, i78-81	2.4	19
220	Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. <i>Modern Rheumatology</i> , 2012 , 22, 849-858	3.3	36
219	Overview of biotherapy in rheumatoid arthritis (RA). <i>Arthritis Research and Therapy</i> , 2012 , 14,	5.7	1
218	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. <i>Modern Rheumatology</i> , 2012 , 22, 498-508	3.3	72
217	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , 2012 , 22, 814-822	3.3	27
216	Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. <i>Leukemia and Lymphoma</i> , 2012 , 53, 616-23	1.9	48
215	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012 , 22, 186-194	3.3	5
214	Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1583-5	2.4	23

213	Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. <i>Clinical Rheumatology</i> , 2012 , 31, 569-74	3.9	31
212	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. <i>Rheumatology International</i> , 2012 , 32, 1511-9	3.6	17
211	Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. <i>Rheumatology International</i> , 2012 , 32, 1617-24	3.6	10
210	Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. <i>Journal of Gastroenterology</i> , 2012 , 47, 540-52	6.9	27
209	Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. <i>Experimental Hematology</i> , 2012 , 40, 279-89	3.1	40
208	Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. <i>Rheumatology</i> , 2012 , 51, 1846-54	3.9	46
207	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 817-24	2.4	88
206	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012 , 22, 327-338	3.3	36
205	Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy. <i>PLoS ONE</i> , 2012 , 7, e37447	3.7	15
204	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012 , 22, 186-94	3.3	1
203	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012 , 22, 327-38	3.3	21
202	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. <i>Modern Rheumatology</i> , 2012 , 22, 498-508	3.3	36
201	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. <i>Modern Rheumatology</i> , 2012 , 22, 814-22	3.3	17
200	Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. <i>Modern Rheumatology</i> , 2012 , 22, 849-58	3.3	12
199	Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2011 , 13, R170	5.7	40
198	Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>Journal of Rheumatology</i> , 2011 , 38, 1258-64	4.1	114
197	Revolutionary change in rheumatoid arthritis management with biological therapy. <i>Keio Journal of Medicine</i> , 2011 , 60, 75-81	1.6	22
196	Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. <i>Internal Medicine</i> , 2011 , 50, 305-13	1.1	53

195	Microscopic polyangitis complicating double carcinoma of the stomach and duodenum: improvement after the resection of these carcinomas. <i>Rheumatology International</i> , 2011 , 31, 105-8	3.6	8
194	Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. <i>Rheumatology International</i> , 2011 , 31, 757-63	3.6	21
193	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , 2011 , 21, 122-133	3.3	57
192	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011 , 21, 343-351	3.3	78
191	Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. <i>Modern Rheumatology</i> , 2011 , 21, 10-15	3.3	40
190	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2148-51	2.4	125
189	Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. <i>Journal of Rheumatology</i> , 2011 , 38, 1585-92	4.1	68
188	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011 , 21, 458-468	3.3	21
187	Fcγ receptor IIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 299-304	2.4	21
186	Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. <i>Rheumatology</i> , 2011 , 50, 1268-74	3.9	51
185	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. <i>Rheumatology</i> , 2011 , 50, 1908-15	3.9	69
184	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
183	Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1208-15	2.4	106
182	Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. <i>Modern Rheumatology</i> , 2011 , 21, 10-15	3.3	27
181	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , 2011 , 21, 122-33	3.3	38
180	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011 , 21, 343-51	3.3	36
179	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs--a multicenter, double-blind, parallel-group trial. <i>Modern Rheumatology</i> , 2011 , 21, 458-68	3.3	10
178	T Helper Type 1-Bias in a Regulatory T Cell-Deficient Mouse Model for Immune Thrombocytopenia. <i>Blood</i> , 2011 , 118, 524-524	2.2	

177	Cytokine profiles of bronchoalveolar lavage fluid in patients with pneumocystis pneumonia. <i>Microbiology and Immunology</i> , 2010 , 54, 425-33	2.7	19
176	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010 , 20, 337-342	3.3	9
175	Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. <i>Lupus</i> , 2010 , 19, 162-9	2.6	38
174	The Japanese experience with biologic therapies for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 644-52	8.1	79
173	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1286-91	2.4	205
172	ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1454-60	4.1	14
171	Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010,		7
170	IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation. <i>Rheumatology</i> , 2010 , 49, 1789-91	3.9	25
169	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010 , 20, 531-538	3.3	56
168	1. Rheumatoid Arthritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010 , 99, 2392-2400	0	2
167	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010 , 20, 337-42	3.3	5
166	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010 , 20, 531-8	3.3	33
165	Gene expression informatics with an automatic histogram-type membership function for non-uniform data. <i>Chem-Bio Informatics Journal</i> , 2010 , 10, 13-23	0.8	
164	Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, 365-72	2.2	10
163	Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. <i>Modern Rheumatology</i> , 2009 , 19, 478-487	3.3	90
162	A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2009 , 19, 273-282	3.3	30
161	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. <i>Modern Rheumatology</i> , 2009 , 19, 12-19	3.3	286
160	Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. <i>Journal of Rheumatology</i> , 2009 , 36, 898-906	4.1	153

159	Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1580-4	2.4	246
158	Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1265-8	3.9	37
157	Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. <i>Arthritis and Rheumatism</i> , 2009 , 61, 305-12		118
156	Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. <i>Rheumatology International</i> , 2009 , 29, 431-6	3.6	23
155	Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 387, 261-5	3.4	45
154	Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1069-72	3.9	81
153	Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. <i>Modern Rheumatology</i> , 2009 , 19, 166-172	3.3	8
152	Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. <i>Internal Medicine</i> , 2009 , 48, 1931-8	1.1	6
151	Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. <i>Rheumatology</i> , 2009 , 48, 198-9	3.9	16
150	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. <i>Modern Rheumatology</i> , 2009 , 19, 12-9	3.3	166
149	Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. <i>Modern Rheumatology</i> , 2009 , 19, 166-72	3.3	4
148	A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2009 , 19, 273-82	3.3	25
147	Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. <i>Modern Rheumatology</i> , 2009 , 19, 478-87	3.3	49
146	Conservative sequences in 3'UTR of TCRzeta mRNA regulate TCRzeta in SLE T cells. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 367, 311-7	3.4	3
145	Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. <i>Cytokine</i> , 2008 , 44, 44-8	4	20
144	Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2008 , 18, 442-446	3.3	16
143	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008 , 18, 146-152	3.3	58
142	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). <i>Modern Rheumatology</i> , 2008 , 18, 447-454	3.3	38

141	Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. <i>Blood</i> , 2008 , 112, 635-43	2.2	211
140	Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 189-94	2.4	321
139	Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse model for Sjögren's syndrome. <i>Current Eye Research</i> , 2008 , 33, 621-9	2.9	28
138	Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. <i>Rheumatology</i> , 2008 , 47, 780-8	3.9	69
137	Critical role of dendritic cells in determining the Th1/Th2 balance upon Leishmania major infection. <i>International Immunology</i> , 2008 , 20, 337-43	4.9	21
136	Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. <i>Internal Medicine</i> , 2008 , 47, 915-23	1.1	74
135	Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion. <i>International Journal of Hematology</i> , 2008 , 87, 520-526	2.3	3
134	Interaction of KLRG1 with E-cadherin: new functional and structural insights. <i>European Journal of Immunology</i> , 2008 , 38, 3354-64	6.1	54
133	Molecular effects to human regulatory T cells by treatment with T cell activation inhibitor and TNF blockade. <i>FASEB Journal</i> , 2008 , 22, 1073.10	0.9	
132	Impaired regulation of BAFF production in monocytes of patients with Sjögren's syndrome. <i>FASEB Journal</i> , 2008 , 22, 664.6	0.9	
131	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008 , 18, 146-52	3.3	28
130	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). <i>Modern Rheumatology</i> , 2008 , 18, 447-54	3.3	19
129	Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2008 , 18, 442-6	3.3	7
128	Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. <i>Modern Rheumatology</i> , 2007 , 17, 92-97	3.3	23
127	Systemic Lupus Erythematosus and Vasculitis 2007 , 310-317		
126	Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases. <i>Drug Target Insights</i> , 2007 , 2, 117739280700200	3.4	6
125	De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation. <i>American Journal of Hematology</i> , 2007 , 82, 162-7	7.1	6
124	Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2007 , 10, 295-299		3

123	Past Japanese successes show the way to accomplish future goals. <i>Trends in Parasitology</i> , 2007 , 23, 260-7.4	8
122	Differences in protein profiles of the isolates of <i>Entamoeba histolytica</i> and <i>E. dispar</i> by surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS) ProteinChip assays. <i>Parasitology Research</i> , 2007 , 102, 103-10	2.4 6
121	Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007 , 26, 1585-9	3.9 37
120	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1162-7	2.4 562
119	Down-regulation of Fas-ligand mRNA in Sjögren's syndrome patients with enlarged exocrine glands. <i>Autoimmunity</i> , 2007 , 40, 497-502	3 6
118	Serum indicators for the diagnosis of pneumocystis pneumonia. <i>Chest</i> , 2007 , 131, 1173-80	5.3 178
117	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2007 , 17, 191-197	3.3 93
116	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007 , 17, 28-32	3.3 56
115	Treatment of inflammatory immunologic disease 3. Anti-TNF therapy in rheumatoid arthritis. <i>Internal Medicine</i> , 2007 , 46, 1311-2	1.1 2
114	Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2007 , 17, 451-458	3.3 121
113	Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. <i>Drug Target Insights</i> , 2007 , 2, 239-47	3.4 2
112	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007 , 17, 28-32	3.3 32
111	Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. <i>Modern Rheumatology</i> , 2007 , 17, 92-7	3.3 12
110	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. <i>Modern Rheumatology</i> , 2007 , 17, 191-7	3.3 49
109	Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2007 , 17, 451-8	3.3 59
108	Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. <i>Journal of Rheumatology</i> , 2007 , 34, 322-31	4.1 190
107	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007 , 17, 178-178	3.3 1
106	TCRzeta mRNA splice variant forms observed in the peripheral blood T cells from systemic lupus erythematosus patients. <i>Seminars in Immunopathology</i> , 2006 , 28, 185-93	10

105	Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2006 , 6, 409-15 ^{2,2}	25
104	Elucidation of apoptosis induced by serum deprivation in cultured conjunctival epithelial cells. <i>British Journal of Ophthalmology</i> , 2006 , 90, 760-4	5.5 22
103	Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. <i>International Immunology</i> , 2006 , 18, 1189-96	4.9 36
102	Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2006 , 16, 85-91	3.3 24
101	DNA microarray gene expression profile of T cells with the splice variants of TCRzeta mRNA observed in systemic lupus erythematosus. <i>Journal of Immunology</i> , 2006 , 176, 949-56	5.3 18
100	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006 , 16, 381-388	3.3 16
99	Guidelines for the proper use of etanercept in Japan. <i>Modern Rheumatology</i> , 2006 , 16, 63-67	3.3 57
98	Molecular abnormalities of T-cells in systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , 2006 , 9, 365-371	2
97	Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. <i>Clinical and Experimental Immunology</i> , 2006 , 144, 335-41	6.2 26
96	Impact of TNF inhibitors on rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2006 , 26, 148-159	10.9 2
95	Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2006 , 16, 85-91	3.3 7
94	Guidelines for the proper use of etanercept in Japan. <i>Modern Rheumatology</i> , 2006 , 16, 63-7	3.3 24
93	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006 , 16, 381-8	3.3 5
92	A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006 , 33, 37-44	4.1 79
91	A splice variant of the TCR zeta mRNA lacking exon 7 leads to the down-regulation of TCR zeta, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells. <i>Journal of Immunology</i> , 2005 , 174, 3518-25	5.3 36
90	Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Allergology International</i> , 2005 , 54, 191-202	4.4 9
89	Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2005 , 15, 4-8	3.3 61
88	T cell abnormalities in systemic lupus erythematosus. <i>Autoimmunity</i> , 2005 , 38, 339-46	3 30

87	Axenic cultivation of <i>Entamoeba dispar</i> in newly designed yeast extract-iron-gluconic acid-dihydroxyacetone-serum medium. <i>Journal of Parasitology</i> , 2005 , 91, 1-4	0.9	29
86	Critical role of the fifth domain of E-cadherin for heterophilic adhesion with alpha E beta 7, but not for homophilic adhesion. <i>Journal of Immunology</i> , 2005 , 175, 1014-21	5.3	29
85	Therapeutic targets of misguided T cells in systemic lupus erythematosus. <i>Inflammation and Allergy: Drug Targets</i> , 2005 , 4, 295-8		4
84	Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2005 , 15, 4-8	3.3	22
83	Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. <i>Journal of Rheumatology</i> , 2005 , 32, 1719-26	4.1	155
82	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1761-9		665
81	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients. <i>Modern Rheumatology</i> , 2004 , 14, 442-6	3.3	15
80	Altered signaling triggered by ligation of the TCR/CD3 receptor in T lymphocytes from patients with systemic lupus erythematosus: the road from anergy to autoimmunity. <i>International Reviews of Immunology</i> , 2004 , 23, 265-72	4.6	18
79	Anti-cytokine biological therapy in RA. <i>Drug Delivery System</i> , 2004 , 19, 95-102	0	
78	TCR zeta mRNA with an alternatively spliced 3'-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex. <i>Journal of Immunology</i> , 2003 , 171, 2496-503	5.3	52
77	Quantitative analysis of lacrimal gland function, apoptotic figures, Fas and Fas ligand expression of lacrimal glands in dry eye patients. <i>Experimental Eye Research</i> , 2003 , 76, 233-40	3.7	23
76	Abnormal protein profiles in tears with dry eye syndrome. <i>American Journal of Ophthalmology</i> , 2003 , 136, 291-9	4.9	147
75	Geographic diversity among genotypes of <i>Entamoeba histolytica</i> field isolates. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 3748-56	9.7	78
74	Immunological characteristics of patients with vernal keratoconjunctivitis. <i>Japanese Journal of Ophthalmology</i> , 2002 , 46, 244-8	2.6	17
73	CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma. <i>American Journal of Hematology</i> , 2002 , 69, 200-4	7.1	21
72	Rapid proliferation of a different clone early after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. <i>International Journal of Hematology</i> , 2002 , 76, 287-9	2.3	1
71	Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients. <i>Clinical and Experimental Immunology</i> , 2002 , 129, 160-8	6.2	37
70	Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands. <i>Clinical and Experimental Immunology</i> , 2002 , 129, 177-82	6.2	27

69	Remarkable genetic polymorphism among <i>Entamoeba histolytica</i> isolates from a limited geographic area. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 4081-90	9.7	82
68	Diagnostic significance of serum soluble transferrin receptors in various anemic diseases: the first multi-institutional joint study in Japan. <i>Haematologia</i> , 2002 , 32, 225-38		14
67	2. Role of adhesion molecules in vasculitis syndrome. <i>Internal Medicine</i> , 2002 , 41, 41-4	1.1	4
66	Successful non-surgical treatment of brain abscess and necrotizing fasciitis caused by <i>Bacillus cereus</i> . <i>Internal Medicine</i> , 2002 , 41, 671-3	1.1	14
65	Parvovirus B 19 infection in adults. <i>Internal Medicine</i> , 2002 , 41, 247-8	1.1	5
64	EA35 Congenital Chagas' disease in Bolivia considered from a result of Xenodiagnosis. <i>Medical Entomology and Zoology</i> , 2001 , 52, 139	0.6	
63	Primary natural killer cell lymphoma of the lacrimal sac. <i>Annals of Hematology</i> , 2001 , 80, 607-10	3	18
62	The other side of TNF-targeted therapy of patients with rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2001 , 3, 1-2	4.9	4
61	Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. <i>Arthritis and Rheumatism</i> , 2001 , 44, 550-60		207
60	Expression of Gab1 lacking the pleckstrin homology domain is associated with neoplastic progression. <i>Molecular and Cellular Biology</i> , 2001 , 21, 6895-905	4.8	15
59	Successful treatment of embryo implantation failure in patients with the Sjögren syndrome with low-dose prednisolone. <i>Fertility and Sterility</i> , 2001 , 75, 640-1	4.8	6
58	Rheumatoid arthritis and tumor necrosis factor alpha. <i>Autoimmunity</i> , 2001 , 34, 291-303	3	13
57	Amebiasis in acquired immunodeficiency syndrome. <i>Internal Medicine</i> , 2001 , 40, 563-4	1.1	8
56	Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease 2001 , 44, 550		2
55	Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. <i>Cytokine</i> , 2000 , 12, 1561-5	4	101
54	Conjunctival epithelium expression of HLA-DR in dry eye patients. <i>Ophthalmologica</i> , 1999 , 213, 16-9	3.7	80
53	Candida pneumonia in a case of polymyositis complicated with interstitial pneumonitis. <i>Japanese Journal of Rheumatology</i> , 1999 , 9, 397-402		
52	DNA polymerase activity in encysting <i>Entamoeba invadens</i> . <i>Parasitology Research</i> , 1999 , 85, 604-6	2.4	6

51	Candida pneumonia in a case of polymyositis complicated with interstitial pneumonitis. <i>Japanese Journal of Rheumatology</i> , 1999 , 9, 397-402		
50	Nosocomial pneumonia likely caused by <i>Stenotrophomonas maltophilia</i> in two patients with polymyositis. <i>Internal Medicine</i> , 1999 , 38, 910-6	1.1	3
49	Defective signal transduction via TCR-CD3 complex in patients with systemic lupus erythematosus. <i>Internal Medicine</i> , 1999 , 38, 169	1.1	1
48	????????????????T?????T????????CD3?????????????. <i>Japanese Journal of Clinical Immunology</i> , 1999 , 22, 403-405		
47	Entamoeba dispar: cultivation with sterilized Crithidia fasciculata. <i>Journal of Eukaryotic Microbiology</i> , 1998 , 45, 3S-8S	3.6	20
46	Up-regulation of alphaEbeta7, a novel integrin adhesion molecule, on T cells from systemic lupus erythematosus patients with specific epithelial involvement. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1456-63		26
45	Granulomatous amoebic encephalitis caused by <i>Acanthamoeba</i> in a patient with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 1998 , 17, 329-32	3.9	22
44	Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis. <i>International Reviews of Immunology</i> , 1998 , 17, 365-81	4.6	15
43	Mutations in T cell receptor zeta chain mRNA of peripheral T cells from systemic lupus erythematosus patients. <i>Journal of Autoimmunity</i> , 1998 , 11, 381-5	15.5	54
42	TCR zeta chain lacking exon 7 in two patients with systemic lupus erythematosus. <i>International Immunology</i> , 1998 , 10, 911-21	4.9	58
41	Respiratory syncytial virus-induced interleukin-4 production by human conjunctival epithelial cells contributes to allergy: preliminary study. <i>Current Eye Research</i> , 1998 , 17, 656-662	2.9	7
40	Studies on Current Trend of Imported Malaria in Japan.. <i>Tropical Medicine and Health</i> , 1998 , 26, 151-156		6
39	Lacrimation and salivation are not related to lymphocytic infiltration in lacrimal and salivary glands in MRL lpr/lpr mice. <i>Advances in Experimental Medicine and Biology</i> , 1998 , 438, 941-8	3.6	13
38	Flow cytometric analysis of surface antigens on human conjunctival epithelial cells. <i>Ophthalmic Research</i> , 1997 , 29, 103-9	2.9	18
37	Evaluation of human conjunctival epithelium by a combination of brush cytology and flow cytometry: an approach to the quantitative technique. <i>Diagnostic Cytopathology</i> , 1997 , 17, 456-60	1.4	20
36	Measurement of interleukin-4 and histamine in superficial cells of conjunctiva in patients with allergic conjunctivitis. <i>Current Eye Research</i> , 1996 , 15, 209-13	2.9	8
35	Interleukin-4 and IgE in seasonal allergic conjunctivitis. <i>Ophthalmologica</i> , 1996 , 210, 325-8	3.7	15
34	Systemic lupus erythematosus with necrotizing vasculitis and upregulated expression of VLA-4 antigen. <i>Clinical Rheumatology</i> , 1995 , 14, 370-4	3.9	6

33	Integrin VLA-5 negative primary plasma cell leukemia. <i>Internal Medicine</i> , 1993 , 32, 565-8	1.1	4
32	Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren's syndrome. <i>Journal of Clinical Laboratory Analysis</i> , 1993 , 7, 180-7	3	95
31	Sero epidemiological Study on Human Toxocariasis in the Rural Sector Around Recife, Northeast Brazil.. <i>Tropical Medicine and Health</i> , 1993 , 21, 255-258		1
30	Clinical studies of renal disorders in patients with rheumatoid arthritis.. <i>Japanese Journal of Clinical Immunology</i> , 1992 , 15, 135-141		
29	The presence of anti-protein A antibodies in patients with rheumatoid arthritis. <i>Scandinavian Journal of Immunology</i> , 1991 , 33, 585-92	3-4	3
28	Reactivity of monoclonal antibodies to species-specific antigens of <i>Entamoeba histolytica</i> . <i>Journal of Protozoology</i> , 1991 , 38, 329-34		11
27	A case report of acquired hypogammaglobulinemia with thymoma (Good syndrome).. <i>Japanese Journal of Clinical Immunology</i> , 1991 , 14, 454-462		
26	Thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus: clinical significance of anti-platelet antibodies. <i>Clinical Immunology and Immunopathology</i> , 1990 , 57, 125-36		16
25	Amebiasis in institutions for the mentally retarded in Kanagawa Prefecture, Japan. <i>Japanese Journal of Medical Science and Biology</i> , 1990 , 43, 123-31		13
24	Amplification of suppressor inducer pathway with monoclonal antibody, anti-2H4, identifying a novel epitope of the common leukocyte antigen/T200 antigen. <i>Cellular Immunology</i> , 1989 , 118, 68-84	4-4	5
23	Functional characterization of the CD45R (2H4) molecule on CD8 (T8) cells in the autologous mixed lymphocyte reaction system. <i>European Journal of Immunology</i> , 1989 , 19, 747-55	6.1	30
22	CCA [N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt], a newly developed immunomodulating drug, suppresses T-cell activation by acting on macrophages. <i>Inflammation</i> , 1989 , 13, 125-35	5.1	5
21	An outbreak of amebiasis in an institution for the mentally retarded in Japan. <i>Japanese Journal of Medical Science and Biology</i> , 1989 , 42, 63-76		20
20	Cellular regulation of anti-nRNP antibody synthesis is different from that of anti-DNA antibody synthesis in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 1988 , 8, 177-83	3.6	1
19	Suppression of in vitro production of anti-U1-ribonucleoprotein antibody by monoclonal anti-idiotypic antibody to anti-U1-ribonucleoprotein antibody. <i>Scandinavian Journal of Immunology</i> , 1988 , 28, 687-96	3-4	2
18	CD11 molecule defines two types of suppressor cells within the T8+ population. <i>Cellular Immunology</i> , 1988 , 111, 398-409	4-4	40
17	A systemic lupus erythematosus patient with cardiac tamponade as a presenting symptom successfully treated with steroid pulse therapy.. <i>Japanese Journal of Clinical Immunology</i> , 1988 , 11, 183-188		
16	Induction of suppression following autologous mixed lymphocyte reaction; role of a novel 2H4 antigen. <i>European Journal of Immunology</i> , 1987 , 17, 97-103	6.1	102

15	The 2H4 molecule but not the T3-receptor complex is involved in suppressor inducer signals in the AMLR system. <i>Cellular Immunology</i> , 1987 , 107, 107-14	4-4	26
14	Defects of autologous mixed lymphocyte reaction-activated immunoregulatory T cells in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Immunology</i> , 1987 , 26, 363-9	3-4	5
13	DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1216-22		4
12	Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes. <i>Arthritis and Rheumatism</i> , 1985 , 28, 873-81		27
11	Spontaneous production of antibodies to deoxyribonucleic acids in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1985 , 35, 47-56		11
10	Suppressor T cell function in patients with rheumatoid arthritis complicated by vasculitis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 752-9		14
9	Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients. <i>Arthritis and Rheumatism</i> , 1984 , 27, 766-73		34
8	Abnormalities of B cell stimulatory factors (BSF) produced by T cells and B cell response to BSF from patients with systemic lupus erythematosus (SLE). <i>Japanese Journal of Clinical Immunology</i> , 1984 , 7, 208-215		2
7	Functional differences of anti-T-cell antibody in patients with systemic lupus erythematosus and ulcerative colitis. <i>Scandinavian Journal of Immunology</i> , 1983 , 18, 521-30	3-4	4
6	Study on DNA-specific suppressor T cell dysfunction in patients with systemic lupus erythematosus (SLE). <i>Japanese Journal of Clinical Immunology</i> , 1983 , 6, 555-560		
5	In vitro immune response of SLE lymphocytes. The mechanism involved in B-cell activation. <i>Scandinavian Journal of Immunology</i> , 1982 , 16, 369-77	3-4	33
4	In vitro anti-DNA antibody synthesis by peripheral blood lymphocytes in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1981 , 21, 237-46		11
3	Mitogenic responses to lipopolysaccharide by B lymphocytes from patients with systemic lupus erythematosus. <i>Scandinavian Journal of Immunology</i> , 1981 , 15, 475-82	3-4	7
2	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients		4
1	T-cell receptor β mRNA with an alternatively spliced 3' untranslated region is generated predominantly in the peripheral blood T cells of systemic lupus erythematosus patients		7